Search CommunityWalk:


Emergent BioSolutions Inc

2273 Research Boulevard
Suite 400
Rockville, MD 20850, USA

Category: Biological Defense; Biotechnology/Biopharmaceutical

Used in the following map:

Maryland Biotech Industry Map

Emergent BioSolutions Inc is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and therapeutics that assist the body's immune system to prevent or treat disease.

Emergent's technologies include: spi-VEC(TM), an oral delivery platform technology based on a live attenuated Salmonella enterica serovar typhi bacterium designed to deliver a wide range of antigens to prevent or treat numerous diseases, including bacterial and viral infections & cancer; MVAtor(TM), designed to share the beneficial properties of an MVA strain formerly used as a smallpox pre-vaccine designed to avoid any potential risk of Bovine Spongiform Encephalitis (BSE); TRU-ADhanCe(TM) technology, enhances the antibody-dependent cellular cytotoxicity (ADCC) potency of immunopharmaceutical product candidates by greater than an order of magnitude; Scorpion(TM) therapeutics, a novel platform for the development of multi-specific protein therapeutics; etc. Its MVAtor(TM) is a tool for gene expression and vaccine development.

Emergent's product pipeline includes: BioThrax® indicated for the active immunization for the prevention of disease caused by Bacillus anthracis; Anthrax Immune Globulin (AIG) indicated as a therapeutic vaccine for anthrax; Typhella, a live attenuated strain of Salmonella typhi vaccine; TRU-016 (Anti-CD37), a novel CD37-targeted therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia; SBI-087 indicated for the treatment of rheumatoid arthritis; Recombinant Anthrax Vaccine (rPA); etc.

Emergent has agreements with Biomedical Advanced Research and Development Authority (BARDA), Temasek Life Sciences Ventures Pte., Ltd., Oxford University, Pfizer Inc, Biological E. Ltd., etc.